Introduction
Global prevalence of HCV infection is estimated to be approximately 3% [1] , with a particularly high burden in many developing countries, including Mongolia [2] .
The majority of individuals with acute HCV infection are asymptomatic but are unable to clear the virus, resulting in 80% chronic infections. Chronic HCV infection progresses to cirrhosis in about 20% of the patients, who then have a 1-4% annual risk of further developing hepatocellular carcinoma [3] . However, new HCV treatment paradigms offer very high cure rates with short treatment durations and few side effects, and have the potential to revolutionize the global management of HCV [4] .
Hepatitis C virus is divided into six major genotypes which share approximately 65% nucleic acid sequence homology [5] , and 80 subtypes based on its extensive genetic heterogeneity. Genotypes 1, 2 and 3 are found throughout the world, genotype 4 is common in North Africa and the Middle East, genotype 5 is common in South Africa and genotype 6 is endemic in South East Asia [6] .
The initial test to screen for HCV infection is based on the use of third generation enzyme immunoassays (EIAs) to detect anti-HCV antibodies against recombinant HCV proteins of the Core, NS3, NS4 and NS5 regions [7] in plasma or serum.
Serologic assays cannot discriminate acute from chronic or resolved infection [8] , so that EIA-positives require the detection of HCV RNA to define active HCV infection. This confirmation step complicates the diagnostic algorithm, especially for limited resource settings. Rapid tests for point of care testing have been developed [9] .
We have developed multiplex serology to simultaneously quantify antibodies to arrays of human papillomaviruses [10] and other viral and bacterial infections [11] using Luminex technology. Antigens used are bacterially expressed, affinity-purified glutathione S-transferase (GST) fusion proteins presenting conformational epitopes [12] . They are bound to individual sets of fluorescent polystyrene beads, and antigen- The present study describes the specific development and validation of a single-step multiplex assay for HCV serology. Five recombinantly expressed, single step affinitypurified proteins (Core, NS3, NS4A, NS5A and NS5B) each from the most common subtypes of HCV (1a, 1b, 2a) are used as antigens. After validation with reference sera of known HCV status, HCV seroprevalence was determined in a seroepidemiological study from Mongolia, a country known to have one of the highest HCV prevalences in the world and where hepatocellular carcinoma is the leading cause of cancer death [13] . 
Materials and Methods

Human sera
Reference sera (n=432) were selected from the diagnostic unit of the Department of Infectious Diseases, University Clinics Heidelberg, Germany. HCV antibody status For the Mongolian study, sera of 1,023 women (median age 36 years, range 16 to 63) participating in a previously conducted cross-sectional population-based study in Ulaanbaatar [14] were analysed. This collection of sera is expected to be well representative of the adult female population of Mongolia. The study was approved by the ethical review committees of the International Agency for Research on Cancer (IARC) and the Ministry of Health in Mongolia, and all study participants signed an informed consent form.
Expression of recombinant GST-HCV-tag proteins in E. coli
Full-length coding sequences of Core and non-structural proteins NS3, NS4A, NS4B, NS5A, NS5B of the three HCV subtypes 1a, 1b and 2a were expressed as double fusion proteins with a N-terminal glutathione S-transferase (GST) and a C-terminal tag epitope derived from the large T-antigen of SV40 in E. coli [15] . Open reading frames were amplified by PCR and cloned into a modified pGEX4T3 vector [15] . The 
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PCR primers are listed in Table 1 . Plasmids pCV-H77(c) subtype 1a [16] , pFK1-9605Con1 subtype 1b [17] and pJ6CF subtype 2a [18] were used as templates.
All clones were verified by commercial sequence analysis (MWG, Ebersberg, Germany).
Fusion proteins of NS4A and NS5A were expressed in E. coli strain BL21 and fusion proteins of Core, NS3 and NS5B in BL21 Rosetta (Invitrogen, Darmstadt, Germany).
Successful full-length antigen expression was verified by anti-tag ELISA as described previously [15] .
Despite confirmed correct sequence, no protein expression for all three NS4B constructs was detectable. This lack of expression is probably caused by the very hydrophobic nature of the NS4B proteins [19] .
Multiplex serology
Multiplex serology was performed as described previously [10] . Briefly, fusion proteins were loaded and affinity-purified on glutathione-casein coupled spectrally distinct fluorescence-labelled polystyrene beads (SeroMap; Luminex, Austin, Texas, USA). Serum samples were incubated at 1:100 final dilution with pooled antigenloaded bead sets. Bound antibodies were quantified with biotinylated goat antihuman IgA, IgM, IgG (Dianova, Hamburg, Germany) and R-phycoerythrin labelled streptavidin in a Luminex 100 analyser as the median R-phycoerythrin fluorescence intensity (MFI) from at least 100 beads of the same bead set. Antigen specific MFI values were calculated as described [10] .
Cut-off definitions for multiplex HCV serology
For each antigen, cut-off values (Table 2) were defined as the mean MFI plus three standard deviations from 235 reference sera negative in commercial HCV antibody screening assay (MEIA). For NS3 of subtype 2a one positive outlier was excluded from the cut-off calculation. For all three NS5B proteins the calculated cut-off was very low and arbitrarily raised to 100 MFI. 
Statistical analysis
After classification of HCV seropositive and seronegative status, kappa values with their corresponding 95% confidence intervals (CI) were computed to estimate assay concordance and reproducibility. Mann-Whitney nonparametric tests were used to evaluate differences in antibody reactivity (MFI values) with individual antigens between HCV seropositive and seronegative samples. three NS3 and NS4A proteins. The false positive reference sera showed higher seroprevalence than the negative sera for each of the proteins, with the highest value for NS5A subtype 1a (24.1%).
Four of the 133 false positive (3.0%) and one of the 235 negative reference sera (0.4%) were discordantly classified by multiplex serology as HCV seropositive (Table   3 ) yielding specificities of 97% and 99.6%, respectively, for these two groups of reference sera. When the false positive and negative reference sera were combined as true negative group, the concordance of HCV serostatus classification by multiplex serology versus the commercial screening (EIA) and validation assays (RNA analysis and Western Blot) was very high with a kappa value of 0.96 (95% CI 0.92-0.99).
When 185 sera from the reference panel containing 67 multiplex serology positive sera were retested a day later with identical batches of antigen-loaded beads, 183 were concordantly classified (98.9%) resulting in a kappa value of 0.98 (95% CI 0.94-1.00) which indicated very good reproducibility of HCV multiplex serology. Both sera discordant upon reproduction belonged to the group of 4 false-positive reference sera that were initially classified positive by multiplex serology.
HCV seropositivity in Mongolian women
HCV serostatus was determined by multiplex HCV serology in 1023 sera representative for the adult female population of Mongolia. Overall HCV seropositivity was 18.9% (Table 3) , and 17.8% when age-standardized to the world population. All of the 193 HCV seropositive women had antibodies against NS3 and Core, none was defined by the alternative HCV serostatus algorithm using positivity for NS3 and two other NS proteins. None of the three subtypes alone offered 100% sensitivity.
HCV seropositivity sharply increased with age from 10.0% in Mongolian women younger than 30 years to 32.0% in women ≥50 years (OR 4.15, 95% CI 2.15-7.99; 
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HCV seropositivity showed no association with education level, number of births, number of induced abortions or life-time number of sexual partners (Table 4) . 
Discussion
Assay development and validation
We developed and validated a multiplex HCV serology assay comprising 5
antigens from each of the 3 most prevalent HCV subtypes, 1a, 1b and 2a. Due to the multiplex format, antibodies against these 15 HCV antigens could be determined and quantified simultaneously. Antibody prevalence for individual proteins differed strongly across reference sera, with Core and NS3 being clearly the most immunogenic. Importantly, cross-reactivity to homologous proteins of all three investigated subtypes of Core and NS3 was very high which may reflect the higher amino acid sequence conservation of these proteins across HCV subtypes as well as the higher antibody titers (indicated by the several-fold higher MFI values, Figure 1) as compared to the NS4 and NS5 proteins. Indeed, an extreme predominance of HCV genotype 1b in Mongolia [20] is known, but no clear differences could be seen in seroprevalences by sub-type. Hence, there was no strong evidence for HCV serotypes and this assay can be expected to be relevant also for populations infected with HCV genotypes 3-6, although direct comparison of the genetic subtype involved in current infections with antibody responses would be needed to fully address this question.
Defining overall HCV seropositivity by including multiple proteins of the same subtype resulted in higher screening specificity in comparison to the commercial HCV antibody screening assay (EIA). However, the exact increase in specificity remains to be determined as the strong reduction of false positives observed in our study is largely based on oversampling this particular group of reference sera. The assay performs very similar to results following confirmation by immunoblot and RNA detection, whilst still retaining absolute sensitivity (98% when restricting the antigens to Core and NS3 only). Improved specificity over EIA could be due to the fact that multiplex HCV serology includes full-length soluble, non-denatured proteins, in which conformational epitopes are likely present, whereas EIA includes peptide antigens in Reactivity to NS4 and NS5 proteins varied strongly among HCV seropositives, but it remains to be determined whether specific NS4 and/or NS5 antibody patterns may be associated with infection or disease status.
In conclusion, this HCV multiplex serology assay appears to be a sensitive, specific and robust assay to detect individuals with current or past HCV infection in a single step. Due to its high-throughput potential and reduced need for confirmatory testing it provides a useful and cost effective tool for large epidemiological studies assessing HCV status. Furthermore, the assay has also been shown to be applicable to dried blood spots [11] .
HCV seropositivity and risk factors in Mongolian women
HCV seropositivity in Mongolian women was high and increased with age, in agreement with a recently reported meta-analysis of HCV seroprevalence (9% in the current study vs. 10% [2] for 20-29 years, 17% vs 12% for 30-39, 25% vs 21% for 40-49 and 32% versus 34% for >50, respectively). Age specific prevalences in our study were also similar to the prevalence of HCV RNA in a single large national survey [20] (10% for 20-29, 12% for 30-39, 24% for 40-49, and 30% for >50, respectively).
A strong association between lifetime number of sexual partners and seropositivity to Human Papillomavirus infection has been previously demonstrated in this study population [14] , but was not apparent for HCV seropositivity, suggesting that sexual transmission of HCV is not common in Mongolia. Furthermore, little difference in HCV prevalence was found by education, occupation or reproductive factors, suggesting that the spread of HCV has been rather similar in different sociocultural groups. Tables   Table 1. Primers used for generation of recombinant GST-HCV-tag Since all three Core constructs were generated with PCR primers matching the 1a sequences, the 1b Core construct has three (T845C, G848T, C851T) and the 2a
Core construct four nucleotide exchanges (A349G, T845C, A847T, C850T), but all of these are silent point mutations.
c Isolate pCV-H77C (Accession number AF009606) was used for subtype 1a, Con1
(AJ238799) for 1b and pJ6CF (AF177036) for 2a. 
